Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year.....
+See More2018-05-08 13:39:00 Tuesday ET

The Trump administration weighs the pros and cons of a potential mega merger between AT&T and Time Warner. Recent stock prices show favorable trends for
2019-03-01 13:36:00 Friday ET

Global economic uncertainty now lurks in a thick layer of mystery. This uncertainty arises from Sino-U.S. trade tension, Brexit fallout, monetary policy nor
2018-05-06 07:30:00 Sunday ET

President Trump withdraws America from the Iran nuclear agreement and revives economic sanctions on Iran for better negotiations as western allies Britain,
2018-01-01 06:30:00 Monday ET

As former chairman of the British Financial Services Authority and former director of the London School of Economics, Howard Davies shares his ingenious ins
2019-11-05 07:41:00 Tuesday ET

The Trump administration expects to reach an interim partial trade deal with China. This interim partial trade deal represents the first phase of a comprehe
2018-05-15 08:40:00 Tuesday ET

Net neutrality rules continue to revolve around the Trump administration's current IT agenda of 5G telecom transformation. Republican Senate passes the